Cargando…

A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease

Therapeutic drug monitoring (TDM) is a useful strategy to optimize biologic medications for inflammatory bowel disease not responsive to standard dosing regimens. TDM is cost effective for anti-tumor necrosis factor agents in the setting of loss of response (reactive TDM). Optimizing drug dosing whe...

Descripción completa

Detalles Bibliográficos
Autor principal:	Vaughn, Byron P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584740/ https://www.ncbi.nlm.nih.gov/pubmed/34768509 http://dx.doi.org/10.3390/jcm10214990

Ejemplares similares

Therapeutic drug monitoring for biological medications in inflammatory bowel disease
por: Cogan, Rachel C., et al.
Publicado: (2022)

Biologic Concentration Testing in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2015)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
por: Wu, Jia-Feng
Publicado: (2022)

Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
por: Kapoor, Akshay, et al.
Publicado: (2021)

Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
por: Papamichael, Konstantinos, et al.
Publicado: (2023)

Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
por: Lee, Scott D., et al.
Publicado: (2021)

Therapeutic drug monitoring in inflammatory bowel disease treatments
por: Wang, Meng-Yao, et al.
Publicado: (2022)

Updates in therapeutic drug monitoring in inflammatory bowel disease
por: Lodhia, Nilesh, et al.
Publicado: (2022)

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
por: Ward, Mark G., et al.
Publicado: (2018)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease
por: Simsek, Melek, et al.
Publicado: (2017)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
por: Martins, Camilla de Almeida, et al.
Publicado: (2022)

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
por: Dreesen, Erwin, et al.
Publicado: (2017)

A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
por: Patel, Sanket, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
por: Little, Robert D., et al.
Publicado: (2022)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2022)

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
por: Deyhim, Tina, et al.
Publicado: (2023)

Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place
por: Truta, Brindusa
Publicado: (2022)

An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
por: Patel, Rajan N., et al.
Publicado: (2020)

Psychological Features in the Inflammatory Bowel Disease–Irritable Bowel Syndrome Overlap: Developing a Preliminary Understanding of Cognitive and Behavioral Factors
por: Petrik, Megan, et al.
Publicado: (2021)

Biological Activities Underlying the Therapeutic Effect of Quercetin on Inflammatory Bowel Disease
por: Lyu, Yong-Li, et al.
Publicado: (2022)

Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
por: Kolho, Kaija-Leena
Publicado: (2021)

Potential Role of Methotrexate Polyglutamates in Therapeutic Drug Monitoring for Pediatric Inflammatory Bowel Disease
por: Morrow, Ryan, et al.
Publicado: (2021)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Therapeutic drug monitoring of biologics in psoriasis
por: Liau, MeiQi May, et al.
Publicado: (2019)

Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
por: Campbell, James P., et al.
Publicado: (2021)

Kidney Biopsy Findings and Clinical Outcomes of US Veterans with Inflammatory Bowel Disease
por: Ravipati, Prasanth, et al.
Publicado: (2023)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
por: Di Paolo, Antonello, et al.
Publicado: (2021)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Biologic targeting in the treatment of inflammatory bowel diseases
por: Bosani, Matteo, et al.
Publicado: (2009)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
por: Sivridaş, Merve, et al.
Publicado: (2023)

Emerging therapeutic options in inflammatory bowel disease
por: Yamamoto-Furusho, Jesus K, et al.
Publicado: (2021)

Catechins and Their Therapeutic Benefits to Inflammatory Bowel Disease
por: Fan, Fei-Yan, et al.
Publicado: (2017)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Medication adherence in inflammatory bowel disease
por: Chan, Webber, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b7kauv9rckec0tc912pialg4qc